Publication of Prospectus and First Dealings

RNS Number : 3423J

Levrett PLC

17 December 2015

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR IN OR INTO, AUSTRALIA, CANADA, JAPAN, THE UNITED STATES OF AMERICA OR SOUTH AFRICA OR ANY JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.

For Immediate Release 17 December 2015

Levrett Plc

("Levrett" or "the Company")

Admission to Trading and First Day of Dealings

Publication of Prospectus

Levrett, a Company formed to acquire a target company (or companies) with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, is pleased to announce that its entire issued ordinary share capital consisting of 95,750,000 Ordinary Shares of £0.001 each (the "Ordinary Shares") will today be admitted to the standard segment of the Official List of the UKLA and to trading on the Main Market for listed securities of the London Stock Exchange (together "Admission"). Dealings are expected to commence at 8:00 a.m. under the TIDM code "LVRT" (ISIN: GB00BYW79Y38).

Levrett is also pleased to announce that copies of the Prospectus in relation to the Admission are available for inspection, subject to applicable securities laws, from the Company's website at www.levrett.com. Defined terms in this announcement shall have the same meanings as in the Prospectus.

Commenting, Pascal Hughes, Chief Executive Officer, said:

"We are very pleased to have successfully concluded the Placing and Admission of Levrett. There are a number of very exciting opportunities in the pharmaceutical and biotechnology sectors which we look forward to exploring further."

Highlights

· Levrett has been formed for the purpose of acquiring a business or businesses operating in the pharmaceutical and biotechnology sector ("the Acquisition").

· The Company will look to acquire a target company with products and technology already at a stage of development that will add value to the target company.

· There remain many categories of serious illness that can and will benefit from technological advances in diagnosis and treatment such as cancer, cardiovascular disease and respiratory disease, together with obesity and diabetes. These areas will be the main, though not the exclusive, focus of the Company.

STATISTICS

Total number of Ordinary Shares issued pre-Admission	50,000,000
Total number of Ordinary Shares issued pursuant to the Placing	45,750,000
Total number of Ordinary Shares in issue on Admission	95,750,000
Placing Price	£0.02
Net Proceeds of the Placing	£915,000
Costs of Admission	£139,897
Market capitalisation of the Company at the Placing Price on Admission	£1.915m